Clinical trials · Illinois
Down Syndrome clinical trials in Illinois
We’re tracking 133 recruiting down syndrome studies with a site in Illinois — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT07135050RecruitingPhase 1/Phase 2
Gene therapy study for Pitt Hopkins syndrome
This trial tests a new gene therapy called MZ-1866 for people with Pitt Hopkins syndrome. The therapy is given as a single injection into the fluid around the brain to help replace the missing or faulty TCF4 gene.
Chicago, IllinoisAges 2–25 - NCT06872125RecruitingPhase 3
Testing zorevunersen for Dravet syndrome
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Chicago, IllinoisAges 2–17 - NCT07742735RecruitingPhase 3
Study of apraglutide for short bowel syndrome with intestinal failure
This study tests a new medicine called apraglutide, given as a shot, to see if it can help adults with short bowel syndrome and intestinal failure reduce their need for intravenous nutrition (parenteral support). The study compares apraglutide to a placebo (a shot with no medicine) to check if it is safe and effective.
Maywood, IllinoisAges 18 years+ - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Bloomington, IllinoisAges 18 years+ - NCT05677100Recruiting
Aortix device for acute heart failure
This trial is testing a small pump placed in the aorta to help the kidneys remove extra fluid when standard IV diuretics aren't working well enough for severe heart failure. It may help you if you're hospitalized and still very congested (swollen, fluid buildup) despite strong water pills.
Chicago, IllinoisAges 21 years+ - NCT06415344Enrolling by invitationPhase 3
Long-term extension of GTX-102 in Angelman syndrome
This study is a long-term follow-up for people with Angelman syndrome who have already taken part in a GTX-102 trial. It tests whether the treatment continues to be safe and helpful over a longer period.
Chicago, IllinoisAges Any age - NCT07181837RecruitingPhase 1/Phase 2
Testing MVX-220 for Angelman Syndrome
This study tests an experimental medicine called MVX-220 to see if it is safe and effective for people with Angelman Syndrome. It includes both children (ages 4-8) and adults (ages 18-50) who can walk independently and have stable seizure medications.
Chicago, IllinoisAges 4–50 - NCT07422480RecruitingPhase 3
Comparing elritercept to epoetin alfa for anemia in MDS needing transfusions
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Skokie, IllinoisAges 18 years+ - NCT06078553Recruiting
Natural history study of congenital myasthenic syndromes (CMS)
This study follows people with congenital myasthenic syndrome (CMS) caused by changes in certain genes (DOK7, MUSK, AGRN, or LRP4) over time. It does not test any new drug, but helps researchers understand how the condition changes and how to plan future treatments.
Chicago, IllinoisAges 2 years+ - NCT07277582RecruitingPhase 2/Phase 3
Study of THRV-1268 for long QT syndrome type 2
This trial tests an investigational drug called THRV-1268 in people with a specific genetic form of long QT syndrome (type 2). The goal is to see if it can safely help control the heart's electrical activity and reduce the risk of dangerous heart rhythms.
Chicago, IllinoisAges 15 years+ - NCT03088020Recruiting
CCHS patient registry for people with PHOX2B gene changes
This study is a registry, meaning it collects health information to better understand congenital central hypoventilation syndrome (CCHS). It enrolls only people whose CCHS has been confirmed by a PHOX2B gene test.
Chicago, IllinoisAges Any age - NCT03339128RecruitingPhase 2
Eluxadoline for diarrhea-predominant IBS in children
This trial tests whether eluxadoline can reduce symptoms of IBS with diarrhea (IBS-D) in children ages 6 to 17. It also asks families to track symptoms with a daily diary to measure whether treatment helps over the study period.
Park Ridge, IllinoisAges 6–17 - NCT03568669Recruiting
Testing thinking and learning in congenital central hypoventilation syndrome
This study looks at thinking and memory in people with congenital central hypoventilation syndrome (CCHS) to better understand how the condition affects the brain. It may help researchers measure changes over time and guide future care.
Chicago, IllinoisAges 3–85 - NCT03708900RecruitingPhase 2
Osilodrostat study for children with Cushing’s syndrome
This Phase 2 study tests how osilodrostat works in children and teens with Cushing’s syndrome—what the drug does in the body, how it affects hormones, and how safely it’s tolerated. It may help families who cannot have immediate surgery or whose surgery has already failed or is still pending.
Chicago, IllinoisAges 2–17 - NCT05640271RecruitingPhase 2
Tocilizumab for acute chest syndrome in sickle cell
This trial studies tocilizumab (a medicine that calms inflammation) to treat acute chest syndrome in people with sickle cell disease. It may help improve symptoms and recovery by targeting key immune signals involved in this complication.
Chicago, IllinoisAges 12 years+ - NCT04165109Recruiting
Down syndrome study to test memory and thinking changes
This study enrolls adults with Down syndrome to better understand how thinking and memory develop and change over time. It may help by building a “trial-ready” group and by measuring thinking in a careful, consistent way.
Park Ridge, IllinoisAges 25–55 - NCT04278404Recruiting
Drug safety study for children already on certain medicines
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Chicago, IllinoisAges birth–20 years - NCT04507997Recruiting
Study of the natural course of Angelman syndrome
This study follows people with Angelman syndrome to understand how their symptoms and development change over time. It may help researchers better describe the condition and support future treatments.
Chicago, IllinoisAges Any age - NCT05052606Recruiting
Turner syndrome patient registry study
This is a registry study that collects health information from people who have Turner syndrome. It helps researchers better understand the condition and guide future care.
Glenview, IllinoisAges Any age - NCT05127226RecruitingPhase 1/Phase 2
Test drug safety for Angelman syndrome in young children
This early-phase study tests a new experimental medicine called ION582 to see if it is safe, tolerable, and how the body processes it in people with Angelman syndrome. It may also look at early signs of how the medicine affects the brain and body, which could guide future treatments.
Chicago, IllinoisAges birth–50 years - NCT05732103RecruitingPhase 1/Phase 2
Testing CTX-712 for AML or high-risk MDS after prior treatment
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
Chicago, IllinoisAges 18 years+ - NCT05947955RecruitingPhase 2
Study drug for infection-related lung failure in adults
This Phase 2 trial tests Rhu-pGSN in adults with acute respiratory distress syndrome (ARDS) caused by an infection. If you qualify, the study may help determine whether the drug improves outcomes in this short-term, life-threatening lung condition.
Chicago, IllinoisAges 18 years+ - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Chicago, IllinoisAges 1–18 - NCT06338267Recruiting
Testing new sensors for Rett syndrome symptoms at home
This study tests new wearable sensors to track symptoms like heart rate and breathing in people with Rett syndrome. If you join, you'll use the sensors at home to help researchers see how symptoms change day to day.
Chicago, IllinoisAges Any age
Down Syndrome trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting down syndrome studies listed above.
- Ann & Robert H. Lurie Children's Hospital of Chicago · 7 studies
- Rush University Medical Center · 6 studies
- Northwestern University · 3 studies
- University of Chicago · 3 studies
- HSHS St. Elizabeth's Hospital · 2 studies
- Loyola University Medical Center · 2 studies
- Advocate Children's Hospital - Park Ridge
- Advocate Good Samaritan Hospital
What taking part in a down syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Down Syndrome trials in other states
Common questions
- Are there down syndrome clinical trials in Illinois?
- Yes. We're currently tracking 133 recruiting down syndrome studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a down syndrome study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a down syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New down syndrome studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.